

Contents

◆ Preface	v
◆ Syllabus	vii

Chapter 1

Introduction to Toxicology and Regulatory Frameworks	1
1.1 Definition and Scope of Toxicology	1
1.1.1 Toxicology	1
1.1.2 Importance of Toxicology in Drug Development	2
1.2 Types of Toxicology	3
1.2.1 General Toxicology	3
1.2.2 Mechanistic Toxicology	4
1.2.3 Descriptive Toxicology	5
1.2.4 Regulatory Toxicology	5
1.3 Regulatory Guidelines for Toxicity Studies	6
1.3.1 OECD Guidelines (Organisation for Economic Co-operation and Development)	6
1.3.2 ICH Guidelines (International Council for Harmonisation)	10
1.3.3 EPA Guidelines (Environmental Protection Agency, USA)	14
1.3.4 Schedule Y Guidelines (India)	16
1.4 Good Laboratory Practice (GLP)	20
1.4.1 OECD Principles of GLP	20
1.4.2 Importance of GLP in Regulatory Submissions	21
1.5 Historical Perspective and Relevance in Drug Discovery	24
1.5.1 Evolution of Toxicology as a Science	24
1.5.2 Role of Toxicology in Modern Drug Development	25

Chapter 2

Preclinical Toxicity Testing Methods	28
2.1 Acute, Sub-Acute, and Chronic Toxicity Studies	28
2.1.1 Oral Toxicity	28
2.1.2 Dermal Toxicity	36
2.1.3 Inhalational Toxicity	43
2.1.4 Study Designs as per OECD Guidelines	48
2.2 Irritation and Sensitization Studies	55
2.2.1 Acute Eye Irritation Tests	55
2.2.2 Skin Sensitization Studies	58
2.2.3 Dermal Irritation and Dermal Toxicity Testing	62
2.3 Test Item Characterization	69
2.3.1 Importance in Regulatory Toxicology	69
2.3.2 Methods and Parameters for Test Item Characterization	69

Chapter 3

Reproductive and Genetic Toxicity Studies	73
3.1 Reproductive Toxicology	73
3.1.1 Segment I: Fertility and Reproductive Performance Studies	74
3.1.2 Segment II: Teratogenicity Studies (Developmental Toxicity)	76
3.1.3 Segment III: Perinatal and Postnatal Studies	79
3.1.4 Male and Female Reproductive Toxicity Studies	81
3.2 Genotoxicity Testing	83
3.2.1 Ames Test (Bacterial Reverse Mutation Assay)	83
3.2.2 In Vitro Micronucleus and Chromosomal Aberration Tests	86
3.2.3 In Vivo Micronucleus and Chromosomal Aberration Studies	88
3.3 Carcinogenicity Testing	94
3.3.1 In Vivo Carcinogenicity Studies	94
3.3.2 Importance in Long-Term Safety Assessment	97

Chapter 4

IND-Enabling Studies and Safety Pharmacology	99
4.1 IND-Enabling Studies	99
4.1.1 Definition of IND	99
4.1.2 Importance of IND in Drug Development	100
4.1.3 Industry Perspective: Key Components of IND Submission	100
4.2 Safety Pharmacology Studies	103
4.2.1 Origin, Concept, and Purpose	103
4.2.2 Importance of Safety Pharmacology	103
4.3 Tier-Based Approach in Safety Pharmacology Studies	103
4.3.1 Tier I: Core Battery Studies	103
4.3.2 Tier II: Supplemental and Follow-Up Studies	107

Chapter 5

Toxicokinetics and Alternative Testing Approaches	111
5.1 Introduction to Toxicokinetics	111
5.1.1 Role in Preclinical Safety Studies	112
5.1.2 Saturation Kinetics: Concept and Relevance	112
5.1.3 Application in Human Risk Assessment	113
5.2 Alternative Methods to Animal Testing	115
5.2.1 Rationale and Ethical Considerations: The 3Rs Principle	115
5.2.2 In Vitro and In Silico Methods	116
5.2.3 Regulatory Acceptance and Future Trends	117

Appendices

1. Appendix A	121
2. Appendix B	122

3. Appendix C	123
4. Appendix D	124
5. Appendix E	125
6. Appendix F	126
 Dr. APJ AKTU Previous Year Question Papers	 129
Model End Term Question Papers	137